



## Beck, Sarah (2014) Are silver products an effective treatment for infection of chronic wounds? [Dissertation (University of Nottingham only)] (Unpublished)

### Access from the University of Nottingham repository:

[http://eprints.nottingham.ac.uk/27066/2/Silver\\_products\\_an\\_effective\\_treatment\\_for\\_managing\\_locally\\_infected\\_chronic\\_wounds\\_\\_a\\_systematic\\_review\\_of\\_the\\_literature.pdf](http://eprints.nottingham.ac.uk/27066/2/Silver_products_an_effective_treatment_for_managing_locally_infected_chronic_wounds__a_systematic_review_of_the_literature.pdf)

### Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

- Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners.
- To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available.
- Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
- Quotations or similar reproductions must be sufficiently acknowledged.

Please see our full end user licence at:

[http://eprints.nottingham.ac.uk/end\\_user\\_agreement.pdf](http://eprints.nottingham.ac.uk/end_user_agreement.pdf)

### A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact [eprints@nottingham.ac.uk](mailto:eprints@nottingham.ac.uk)

**Silver products- an effective treatment for  
managing locally infected chronic wounds; a  
systematic review of the literature**

*Dissertation submitted for Master of Nursing Science,  
School of Health Sciences  
University of Nottingham*

By Sarah Beck

Word Count- 15, 998

I declare that this dissertation is all my own work

Signed-

Date-

# *Acknowledgements*

I would firstly like to thank my dissertation supervisor Andy Meal, for his ongoing support during the process of carrying out this systematic review; even if at times when I may have made "fatal" mistakes.

I would also like to thank my flatmates for their support, I don't think they ever want to hear about silver dressings ever again.

I would also like to thank my Dad who gave up his time to help me proof read this review and many of my nursing essays in the past.

I would also like to thank my Mum; without her support over the years I highly doubt I would have ever been able to go to University. When I was in primary school, and my friends were outside having fun, I would be sitting inside doing 11 plus papers. I was not grateful at the time, but I am now.

I also should probably just mention my brother James... how he has helped I am not sure, he is more of a distraction; bringing round his dirty washing for me to do.

# Contents

## Contents of Tables, boxes and Flowcharts

Abstract	Page number
<b>1. CHAPTER 1- Introduction.....</b>	<b>1</b>
<b>2. Chapter 2- Background.....</b>	<b>2</b>
2.1 A background to wounds and wound infection.....	2
2.2 Epidemiology and economics .....	4
2.2.1 Chronic wounds.....	4
2.2.2 Infected wounds.....	4
2.2.3 Silver.....	5
2.3 Topical antimicrobials.....	5
2.4 Existing systematic reviews and randomised controlled trials.....	6
2.5 Aims and objectives.....	7
2.6 Conclusion.....	9
<b>3. CHAPTER 3- Research methods.....</b>	<b>10</b>
<b>Part 1- Methodology</b>	
3.1 Introduction.....	10
3.2 Systematic reviews.....	10
3.2.1 Wound care research.....	12
<b>Part 2- Methods</b>	
3.3 Review Question.....	12
3.3.1 Study Design.....	13
3.3.2 Population.....	14
3.3.3 Intervention.....	15
3.4 Search Strategy.....	16
3.4.1 Information sources.....	16
3.4.2 Searches performed.....	17

3.5	Study Selection Criteria.....	19
3.6	Quality Assessment.....	20
3.7	Data Extraction.....	24
3.8	Data Synthesis.....	25
3.9	Conclusion.....	25
<b>CHAPTER 4- Results.....</b>		<b>26</b>
4.1	Introduction.....	26
4.2	Search results.....	26
4.2.1	Results from effectiveness search strategy.....	26
4.2.2	Results from adverse effect search strategy.....	29
4.3	Outcome results.....	31
4.3.1	Effectiveness of silver products.....	31
4.3.2	Adverse effects of silver products.....	38
4.4	Quality assessment.....	42
4.4.1	Quality of included studies from effectiveness search.....	42
4.4.2	Quality of adverse effects data.....	47
4.5	Conclusion.....	49
<b>CHAPTER 5- Discussion.....</b>		<b>50</b>
5.1	Introduction.....	50
5.2	Primary objectives- Effectiveness.....	50
5.3	Secondary objectives- Adverse effects.....	57
5.4	Final objective.....	59
5.5	Further discussion from reviewing the literature.....	59
5.5.1	Publication date; Lazareth et al (2008).....	59
5.5.2	A lack of consensus of the definition of infection.....	62
5.5.3	Challenges with conducting wound care research.....	65
5.6	Conclusion.....	66

<b>CHAPTER 6- Limitations and Conclusions.....</b>	<b>67</b>
6.1 Introduction.....	67
6.2 Appraisal of the quality/ limitations of this review.....	67
6.3 Recommendations for practice.....	69
6.4 Conclusions from conducting this systematic review.....	70

**Appendices**

**References**

# *Contents of boxes flowcharts, tables and appendices*

## **List of Boxes**

### *Chapter 2*

- 2.1- Stages of wound healing
- 2.2- Comparison of signs and symptoms of infection in chronic and acute wounds
- 2.3- Study objectives

### *Chapter 3*

- 3.1- Structured review question (PICOS format)
- 3.2- Inclusion/ exclusion criteria
- 3.3- Types of biases
- 3.4- Methods used to protect against biases
- 3.5- Adverse effect quality assessment questions
- 3.6- Adverse effect data extraction criteria

### *Chapter 5*

- 5.1- Profile of patients in community setting
- 5.2- Comparison of dressings in the study conducted by Harding et al (2012)
- 5.3- “two week challenge”; criteria to be considered after two weeks of treatment
- 5.4- Adverse effects terminology

### *Chapter 6*

- 6.1- Recommendations for practice

## **List of flow diagrams**

### *Chapter 4*

- Flow diagram 1- Effectiveness search results
- Flow diagram 2- Adverse effect search results

## **List of tables**

### *Chapter 4*

1. Beele et al (2010) results table
2. Lazareth et al (2012) results table
3. Woo et al (2012) results table
4. Harding et al (2012) results table
5. Miller et al (2010) results table
6. Adverse effect results of RCTs with clear control groups
7. Adverse effect results, Harding et al (2012)
8. Adverse effect results, Miller et al (2010)
9. Adverse effects of observational studies
10. Adverse effect quality assessment, RCTs
11. Adverse effect quality assessment, observational studies

## **Appendices**

### *Chapter 2*

1. Table comparing systematic reviews

### *Chapter 3*

2. Effectiveness search strategy
3. Adverse effects search strategy

### *Chapter 4*

4. Table summarising characteristics of RCTs included in review
5. Table summarising characteristics of observational studies included in the review

### *Chapter 6*

6. Table displaying RCTs from this review and from the review conducted by Lo et al (2008)
7. Population Characteristics of RCTs included in the review



# Abstract

**Aim;** To identify whether silver is an effective treatment for infected chronic wounds and to identify any adverse effects.

**Background;** Conflicting evidence exists around the effectiveness and adverse effects of silver products which has led to considerable confusion regarding this treatment in practice. With some previous systematic reviews and RCTs identifying that not enough evidence exists to recommend the use of silver products. However, a systematic review conducted by Lo et al (2008) identified that silver was an effective product for wound healing and reduction of infection levels, therefore it was important to identify if any RCTs had been published from this date to add weight to these conclusions.

**Methods;** A systematic review of the literature was conducted using two search strategies in order to capture both effectiveness data (RCTs), and adverse effect data (RCTs & observational studies). For effectiveness searched; databases were searched from 2008- January 2014 using Cochrane CENTRAL, MEDLINE and EMBASE- including only randomised controlled trials. Adverse effects data was extracted from from the effectiveness results, with the additional searches performed to capture observational studies. This search was conducted from 1950- January 2014 using MEDLINE, EMBASE and CINAHL databases.

**Results;** In total 5 RCTs and 4 observational studies were identified for inclusion in the review. It was identified that silver products are an effective treatment for infected chronic wounds, based on statistically significant results regarding wound healing and infection levels in the included controlled studies- and in combination with the results from the systematic review conducted by Lo et al (2008). Additionally, no serious adverse effects were identified.

**Conclusion;** This systematic review strengthens the case for the use of silver products on managing locally infected chronic wounds. However, the use of silver must be accompanied by a thorough wound assessment; a “two week challenge” is recommended before reassessing for alternative treatment options.

# References

- Anon (2010) NHS wastes millions on wound dressings that contain silver amid doubts over effectiveness, experts say. **The Telegraph** [online] Available at: <http://www.telegraph.co.uk/health/healthnews/7591908/NHS-wastes-millions-on-silver-wound-dressings-that-kill-infections.html> [Accessed 10th March 2014]
- Audit Commission (1999) **First Assessment; a review of District Nursing services in England and Wales**. London: Audit Commission
- Bale, S., Harding, K and Leaper, D (2000) **An introduction to wounds**. Dorset: Drogher Press.
- Beele, H., Meuleneire, F., Nahuys, M., Percival, S (2010) A prospective randomised open label study to evaluate the potential of new silver alginate/carboxymethylcellulose antimicrobial wound dressing to promote wound healing **International Wound Journal** 7(4) pp.262- 270
- Bergin, S and Wraight, P (2006) Silver based wound dressings and topical agents for treating diabetic foot ulcers. **Cochrane database of systematic reviews**. CD005082
- Best Practice Statement (2010) The use of topical antiseptic/antimicrobial agents in wound management. **Wounds UK** [online]. Available at: [www.wounds-uk.com/pdf/](http://www.wounds-uk.com/pdf/)
- Bhattacharyya, M and Bradley, H (2006) Management of a difficult-to-heal chronic wound infected with methicillin-resistant staphylococcus aureus in a patient with psoriasis following a complex knee surgery. **Lower Extremity Wounds** 5(2) pp. 105- 108
- Bowler PG, Duerden BI and Armstrong, DG (2001) Wound microbiology and associated approaches to wound management. **Clinical Microbiology Review** 14(2) pp. 244- 269
- Brown, Brunnhuber et al (2006) **How to formulate research recommendations**. 333 pp. 804- 806

Carter, M., Tingley-Kelley, K and Warriner, R (2010) Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: A systematic review and meta-analysis. **American Academy of Dermatology** 63(4) pp. 668- 679

Centre for Reviews and Dissemination (CRD) (2009) **Systematic Reviews; CRD's guidance for undertaking reviews in healthcare**. York: CRD

Chambers, H., Dumville, J and Cullum, N (2007) Silver treatments for leg ulcers: a systematic review **Wound Repair and Regeneration** 15(2) pp. 165- 173

Coalition for evidenced based policy (2010) **Checklist for reviewing a randomized controlled trial of a social program or project, to assess whether it produced valid evidence** [online] Available at: <http://coalition4evidence.org/wp-content/uploads/2010/02/Checklist-For-Reviewing-a-RCT-Jan10.pdf> [Accessed 06/03/2014]

Cochrane Wounds Group (2014) **Resources for review authors** [online] Available at: <http://wounds.cochrane.org/resources-review-authors> [Accessed 07/02/2014]

Conforth, A (2013) Holistic wound assessment in primary care. **Wound Care** 18(sup 8) pp. 28- 34

Coutts, P., and Sibbald RG (2005) The effect of a silver containing Hydrofiber® dressing on superficial; wound bed and bacterial balance of chronic wounds. **International Wound Journal** 2(4) pp. 348- 346

Critical Appraisal Skills Programme (CASP) (2013) **Making sense of evidence** [online] Available at: <http://www.casp-uk.net/> [Accessed 07/02/2014]

Cutting, K and White, R (2005) Criteria for identifying wound infection revisited. **Ostomy Wound Management** 51(1) pp. 28- 34.

Cutting, K., White, R and Edmonds, M (2007) The safety and efficacy of dressings with silver- addressing clinical concerns. **International Wound Journal** 4(2) pp. 177- 184

Dealey, C (2012) **The care of wounds; a guide for nurses 4<sup>th</sup> ed**. Chichester: Wiley- Blackwell.

- Department of Health (DOH) (2008) **High Quality Care for All; NHS next stage review final report**. London: The Stationery Office
- Department of Health (DOH) (2010) **Healthy lives, healthy people: our strategy for public health in England**. London: Stationery Office
- Department of Health (DOH) (2013) **Care in local communities; a new vision and model for district nursing**. Leeds: DOH
- Diabetes UK (2010) **Diabetes in the UK 2010: Key statistics on diabetes** [online]  
Available at:  
[http://www.diabetes.org.uk/Documents/Reports/Diabetes\\_in\\_the\\_UK\\_2010.pdf](http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf)  
[Accessed 23rd October 2013]
- Dowsett, C (2004) The use of silver-based dressings in wound care. **Nursing Standard** 19(7) pp. 56- 60
- Drew, P., Posnett, J and Rusling, L (2007) The cost of wound care for a local population in England. **International Wound Journal**. 4(2) pp.145- 155
- Enoch, S and Harding, K (2003) Wound bed preparation: the science behind the removal of barriers to healing. **Wounds** 15(7) pp.213- 229
- European Wound Management Association (EWMA) (2008) **Position Document: Hard-to-heal wounds: a holistic approach**. London: MEP Ltd
- European Wound Management Association (EWMA) (2010) Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. **Journal of Wound Care** 19(6) pp. 239- 268
- Flanagan, M (2005) Barriers to the implementation of best practice in wound care. **Wounds UK** 1; pp.74- 82
- Fong, J and Wood, F (2006) Nanocrystalline silver dressings in wound management: a review. **International Journal of Nano medicine**. 1(4) pp. 441-449
- Glasziou, P., Irwig, L., Bain, C and Graham, C (2001) **Systematic reviews in healthcare; a practical guide**. Cambridge: Cambridge University Press.

Gottrup, F., Cullen, B., Karlsmark, T., Bischoff-Mikkelsen, M., Nisbet, L and Gibson, M (2013) Randomized controlled trial on collagen/ oxidized regenerated cellulose/ silver treatment **Wound Repair and Regeneration** 21(2) pp.216- 225

Grothier, L and Pardoe, A (2013) Chronic wounds: management of healing and wellbeing. **British Journal of Nursing** 22(12) pp. 24- 30.

Hampton, S and Collins, F (2004) **Tissue Viability**. London: Whurr Publishers Ltd.

Harding, K., Gottrup, F., Jawień, A., Mikosiński, J., Twardowska-Sauchka, K., Kaczmarek, S., Sopata, M., Shearman, C., Pieronne, A and Kommala, D (2012) A prospective, multi-centre randomised, open label parallel study to evaluate the effects of Aquacell® Ag and Urgotul® silver dressing on the healing of chronic venous leg ulcers **International Wound Journal** 9(3) pp. 285- 294

Higgins, JPT and Green, S (editors) (2008) **Cochrane Handbook for Systematic Reviews of Interventions**. Chichester: John Wiley & Sons.

Hope, J (2010) NHS 'wastes £25m on silver dressings that don't beat bugs'. **The Daily Mail** [online] Available at: <http://www.dailymail.co.uk/health/article-1266093/NHS-wastes-25m-silver-dressings-dont-beat-bugs.html> [Accessed 10th March 2014]

Hulley, S., Cummings, S., Browner, W., Grady, D and Newman, T (2013) **Designing Clinical Research** 4<sup>th</sup> ed. Philadelphia: Lippincot and Williams.

International consensus (2012). **Appropriate use of silver dressings in wounds**. An expert working group consensus. London: Wounds International.

Jhass, P (2011) Infected wounds: improving outcomes and managing costs. **British Journal of Healthcare management** 17(11) pp. 541- 545

Joint Formulary Committee (BNF) (2012). **British National Formulary**. 63<sup>rd</sup> ed. London: BMA and Royal Pharmaceutical Society of Great Britain.

Kammerlander, G., Afardeh, R., Baumgartner, A., Berger, MM., Fischelmayer, K., Hirschberger, G., Hangler, W and Huber, A (2008) Clinical experiences of using a silver hydro-alginate dressing in Austria, Switzerland and Germany. **Journal of Wound Care** 17(9) pp.384- 388

- Katz, M (2013) **Multivariable Analysis; a practical guide for clinicians and public health researchers 3<sup>rd</sup> ed.** Cambridge: Cambridge University Press.
- Khan, K., Kunz, R., Kleijnen, J and Antes, G (2011). **Systematic reviews; to support evidence based medicine 2<sup>nd</sup> ed.** London: Hodder Arnold
- Khan, k., Riet, G., Glanville, J., Sowden, A and Kleijnen, J (Eds.) (2001) **Undertaking systematic reviews of research on effectiveness; CRD's guidance for those carrying out or commissioning reviews report 4** (2<sup>nd</sup> ed.) York: NHS Centre of Reviews and Dissemination.
- Lansdown, A (2004). A review of the use of silver in wound care: facts and fallacies. **British Journal of Nursing.** 13(6) pp. 6- 19.
- Lazareth, I., Meaume, S., Sigal-Grinberg, ML et al (2008) The role of a silver-releasing lipidocolloid contact layer in venous leg ulcers presenting inflammatory signs suggesting heavy bacterial colonisation: results of a randomized controlled study. **Wounds** 20(6) pp. 158- 166
- Lazareth, I., Meaume, S., Sigal-Grinberg, ML., Combemale., Guyadec, T., Zagnoli, A., Perrot, JL., Sauvadet, A and Bohbot, S (2012) Efficacy of a silver lipidocolloid dressing on heavily colonised wounds: a republished RCT **Journal of Wound Care** 21(2) pp.96- 102
- Leaper, D (2006). Silver dressings; their role in wound management. **International Wound Journal.** 3(4) pp. 282- 294
- Leaper, D (2011). An overview of the evidence on the efficacy of silver dressings. **Journal of Wound Care.** 20(3)pp. 8- 14.
- Leaper, D and Drake, R (2011). Should one size fit all? An overview and critique of the VULCAN study on silver dressings. **International Wound Journal.** 8(1) pp. 1- 4
- Lo, S., Chang, C., Hu, W., Hayter, M and Chang, Y (2008) The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: a meta-analysis. **Journal of Clinical Nursing.** 18(5) pp. 716- 728

Loke, Y., Price, D and Herxheimer, A (2008) Adverse effects. In: Higgins, J and Green, S (Ed.) **Cochrane Collaboration for systematic reviews of interventions**. Chichester: John Wiley and Sons.

Meaume, S., Truchett, Cambazard, F et al (2012) A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology –Nano-Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. **Wound Repair and Regeneration** 20(4) pp.500- 511

Meaume, S., Vallet, D., Morere, MN and Teot, L (2005) Evaluation of a silver relieving hydroalginate dressing to minimise the risk of local infection in colonised chronic wounds. **Journal of Wound Care** 14(9) pp. 411-9

Medicines and Medical Devices (MHRA) (2014) **Clinical trials for medicines: safety reporting- SUSARs and DSURs** [online] available at:

<http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Clinicaltrials/Safetyreporting-SUSARsandASRs/#I3> [Accessed 12<sup>th</sup> March 2014]

Michaels JA, Campbell B, King B, et al (2009). Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). **Br J Surg** 96(10): 1147-56.

Miller, C., Carville, K, Newall, N., Kapp, S., Lewin, G., Karimi, L and Santamaria, N (2011) Assessing bacterial burden in wounds: comparing clinical observation and wound swabs. **International Wound Journal** 8(1) pp. 45- 54.

Miller, C., Newall, N., Kapp, S., Lewin, G., Karimi, L (2010) A randomized-controlled trial comparing cadexomer iodine and nanocrystalline silver on the healing of leg ulcers **Wound Repair and Regeneration** 18(4) pp. 359- 367

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. **PLoS Med** 6(7): e1000097. doi:10.1371/journal.pmed.1000097

Mulrow, CD (1994) Systematic Reviews: Rationale for systematic reviews. **British Medical Journal**. 309: pp. 597- 599.

Munter, K., Beele, H., Russell, L., Crespi, A., Grochenig, E., Basse, P., Alikadic, N., Fraulin, F., Dahl, C and Jemma, AP (2006) Effect of sustained silver-releasing dressing on ulcers with delayed wound healing: the CONTOP study. **Journal of Wound Care** 15(5) pp. 199- 206

National Prescribing Centre (2010) **Evidenced-based prescribing of advanced wound dressings for chronic wounds in primary care**. MeReC Bullitin 21, 1

Office of National Statistics (2011) **Office of National Statistics population projections 2035, 2010 based** [online] Available at:

<http://www.statistics.gov.uk/hub/population/ageing/older-people> [Accessed 28th November 2012]

Opananon, S., Muangman, P and Namviriyachote, N (2010) Clinical effectiveness of alginate silver dressing in outpatient management of partial-thickness burns.

**International Wound Journal** 7(6) pp. 467- 471

Paddock, HN., Fabia, R., Giles S, et al (2007) A silver impregnated antimicrobial dressing reduces hospital costs for pediatric burn patients. **J Paediatr Surg** 42(1) pp.211-213.

Parker, K (2012) Psychosocial effects of living with a leg ulcer. **Nursing Standard** 26(45) pp. 52- 62

Plichta, S and Kelvin, E (2013) **Munro's Statistical Methods for Health Care Research** 6<sup>th</sup> ed. China: Lippincott Williams and Wilkins.

Poon, V and Burd, A (2004) In vitro cytotoxicity of silver: Implication for clinical wound care. **Burns** 30 (2) pp. 140- 147

Pragnell, J and Neilson, J (2010) The social and psychological impact of hard-to-heal wounds. **British Journal of Nursing** 19(19) pp. 1248-1252

Richards, AJ., Hagelstein, SM., Pale, GK, Ivins, NM., Sweetland, HM and Harding, KG (2011) Early use of negative pressure therapy in combination with silver dressings in a difficult breast abscess. **International Wound Journal** 8(6) pp. 608- 611



Richards, K., Chadwick, P (2011) Addressing local wound infection with a silver-containing, soft-silicone foam dressing: A case series. **The Diabetic Foot Journal** 14(2) pp. 90- 95

Royal Collage of Nursing (2013) **District Nursing- harnessing the potential; the RCN's UK position on district nursing.** London: RCN

Scottish Intercollegiate Guideline Network (SIGN) (2010) **Management of Chronic Venous Leg Ulcers; a national clinical guideline.** Edinburgh: SIGN

Shepherd, J and Nixon, M (2013) Standardising wound care documentation in clinical practice: The wound healing assessment and monitoring (WHAM) tool. **Wounds UK** 9(1) pp. 62- 66

Sibbald, G., Woo, K and Ayello, E (2007) Increased bacterial burden and Infection: NERDS and STONES. **Wounds UK** 3(2) pp. 25- 46

Siddiqui and Bernstein (2010) Chronic wound infection: facts and controversies. **Clinics in dermatology.** 28(5) pp. 519- 526

Storm- Versloot, N., Vos, G., Ubbink, T and Vermeulen, H (2010) Topical silver for preventing wound infection. **Cochrane database systematic review.** 17(3): CD006478

Tay, L and Macera, L (2011). Evidenced base review of silver dressing use on chronic wounds. **American Academy of nurse practitioners.** 23(4)pp. 183-192

Templeton, S (2005) Management of Chronic Wounds: the role of silver containing dressings. **Primary Intention** 13(4) pp. 170- 179

The Queens Nursing Institute (2009) **2020 vision; focusing on the future of district nursing.** London: The Queens Nursing Institute.

Trial, C., Darbas, H., Lavigne, J-P., Sotto, A., Simoneau, Tillet, Y and Teot, L (2010) Assessment of the antimicrobial effectiveness of a new silver alginate wound dressing: a RCT **Journal of Wound Care** 19(1) pp. 20- 26

Truchetet, F., Guibon, O and Meaume, S (2012) Clinicians' rationale for using a silver dressing: the French OMAg+E observational study. **Journal of Wound Care** 21(12) pp. 620- 625

- Upton, D., Hender, C and Solowiej, K (2012) Mood disorders in patients with acute and chronic wounds: a health professional perspective. **Journal of Wound Care** 21(1) pp. 42-48
- Verdú Soriano, J., Rueda López, J., Martínez Cuervo, F and Soldevilla Agreda, J (2004) Effects of an activated charcoal silver dressing on chronic wounds with no clinical signs of infection. **Journal of Wound Care** 13(10) pp. 421- 3
- Vermeulen, H., Vanhattern, M., Storm- Versloot, N and Ubbink, T (2007) Topical silver for treating infected wounds. **Cochrane database systematic review**. 24(1): CD005486
- Wasiak, J., Cleland, H., Campbell, F and Spinks, A (2013) Dressings for superficial partial thickness burns. **Cochrane Database for Systematic Reviews** 8(4): CD002106
- White, R (2001). A historical overview of the use of silver in wound management. **British Journal of Nursing**. 10(15) pp. 3-8.
- White, R (2010). Silver-containing dressings: availability concerns. **Ostomy Wound Manage**; 56(8): 6-7
- Wilkinson, L., White, R and Chipman, J (2011) Silver and nanoparticles of silver in wound dressings: a review of the efficacy and safety in wound dressings. **Journal of Wound Care** 20(11) pp.543- 549
- Winter, GD (1962) Formation of scab and rate of epithelialization of superficial wounds in the skin of the young domestic pig. **Nature** 193(5)pp. 293- 294
- Wong, S., Wilczynski, N and Haynes, R (2006) Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. **Journal of the Medical Library Association** 94(1) pp. 41- 47.
- Woo, KY., Coutts, PM and Sibbald, RG (2012) A randomized controlled trial to evaluate an antimicrobial dressing with silver alginate powder for the management of chronic wounds exhibiting signs of critical colonization. **Advances in skin and wound care** 25(11): 503-8

World Union of Wound Healing Societies (WUWHS) (2008) **Principles of best practice: wound infection in clinical practice; an international consensus.**

London: MEP

Wounds International (2012) **Optimising wellbeing in people living with a wound** [online] available at:

[http://www.woundsinternational.com/pdf/content\\_10309.pdf](http://www.woundsinternational.com/pdf/content_10309.pdf) [Accessed 10th March 2014]

# Appendix 1

Table 1, Comparison of systematic reviews

Reference	Title	Studies included	Objectives	Adverse effects	Conclusions Made
<b>Carter, Tingley-Kelley and Warriner (2010)</b>	Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: A systematic review and meta-analysis	10 RCT's were selected for inclusion - searches conducted up to 2008	1) Conduct a systematic review of silver dressings and treatments in wounds focusing on healing outcome and parameters; and 2) attempt a meta-analysis for these parameters	- Does not look at the adverse effects of silver products	Some evidence that silver-impregnated dressings improve the short-term healing of wounds and ulcers; long term effects remain unclear. Clinical trial data with longer follow-up times are needed to address these issues.
<b>Chambers, Dumville and Cullum (2007)</b>	Silver treatments for leg ulcers: a systematic review	9 RCT's were selected for inclusion	To determine the quantity and quality of current research on the effectiveness of silver based dressings and topical agents for the treatment of leg ulcers. Involves RCT's looking at the effects of silver-based dressings and topical agents for leg ulcer healing.	- Does not look at the adverse effects of silver products	Studies provided inconsistent evidence regarding the effects of silver-based dressings and topical agents on wound healing. Studies generally provided poor evidence due to a lack of statistical power, poor study designs, and incomplete reporting. Concludes that the current evidence base on the use of silver-based products is limited- both the quantity and quality of available evidence. Highlights the need for more rigorous research to be carried out before the routine use of silver on leg ulcers is justified.
<b>Lo et al (2008)</b>	The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: a meta-analysis	8 RCT's and meta-analysis performed on the data from 1399 participants.	The purpose of the study was to examine the efficacy of silver-releasing dressings in the management of non-healing chronic wounds.	- Does comment on the adverse effects found in the RCT's it reviewed	Found that silver dressings significantly improved wound healing, reduced odour and pain related symptoms, decreased wound exudates and had prolonged dressing wear time when compared with alternative wound care approaches. In all studies indicated an improved quality of life using silver dressings in wound management with no associated severe adverse effects.
<b>Vermeulen et al (2007)</b>	Topical silver for treating infected wounds	Only 3 RCT's were found in total for inclusion in the review. With a total of 847 participants	To evaluate the effects on wound healing of topical silver and silver dressings in the treatment of contaminated and infected acute or chronic wounds.	- Does comment on the adverse effects found in the randomised control trials it reviewed. (see review)	Only three trials with a short follow-up duration were found. There was insufficient evidence to recommend the use of silver containing dressings or topical agents for the treatment of infected or contaminated chronic wounds.

# Appendix 2

## Effectiveness Search Strategies

**Medline using OVID format** using Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE. 2 search strategies; sensitivity-maximizing version and a sensitivity- and precision-maximizing version (Higgins and Green, 2008) (It is recommended that searches for trials for inclusion in Cochrane reviews begin with the sensitivity-maximizing version in combination with a highly sensitive subject search. If this retrieves an unmanageable number of references the sensitivity- and precision-maximizing version should be used instead)

### **Medline search strategy, OVID format, sensitivity- maximising version (2008)**

#1 randomized controlled trial.pt.

#2 controlled clinical trial.pt.

#3 randomized.ab.

#4 placebo.ab.

#5 drug therapy.fs.

#6 randomly.ab.

#7 trial.ab.

#8 groups.ab.

#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8

#10 exp animals/ not humans.sh.

#11 #9 not #10

#12 silver.mp. or silver compounds/ or silver nitrate/ or silver sulfadiazine/

#13 infection.mp. or wound infection/

#14 chronic.mp. or chronic disease/

#15 wound.mp. or wound healing/ or skin ulcer/

#16 #11 and #12 and # 13 and #14 and #15

#17 limit #16 to yr= 2008- 2014

**Medline search strategy, OVID format, sensitivity- and precision-maximizing version (2008)**

#1 randomized controlled trial.pt.

#2 controlled clinical trial.pt.

#3 randomized.ab.

#4 placebo.ab.

#5 clinical trials as topic.sh.

#6 randomly.ab.

#7 trial.ti

#8 #1 or #2 or #3 or #4 or #5 or #6 or #7

#9 exp animals/ not humans.sh.

#10 #8 not #9

#11 silver.mp. or silver compounds/ or silver nitrate/ or silver sulfadiazine/

#12 infection.mp. or wound infection/

#13 chronic.mp. or chronic disease/

#14 wound.mp. or wound healing/ or skin ulcer/

#15 #10 and #11 and #12 and #13 and #14

#16 limit #15 to yr= 2008- 2014

**EMBASE search strategy, OVID format filter from Wong et al, 2006**

#1 random:.tw.

#2 placebo:.mp.

#3 double-blind:.tw.

#4 #1 or #2 or #3

#5 silver.mp. or silver chloride/ or silver derivative/ or silver dressing/ or silver impregnation/ or silver nanoparticle/ or silver nitrate/ or sulfadiazine silver/

#6 exp infection/ or infection.mp. or wound infection/

#7 chronic.mp. or chronic wound/

#8 exp wound/ or wound.mp. or wound care/ or wound complication/ or wound healing/

#9 #5 and #6 and #7 and #8

#10 #4 and #9

#11 limit #10 to yr= 2008- 2014

**CENTRAL- Cochrane Central Register of Controlled trials**

#1 chronic

#2 silver

#3 wound

#4 infection

#5 #1 and #2 and #3 and #4

# Appendix 3

*Adverse effects search strategies*

**Medline using OVID format (1946 to jan wk 3 2014) searches on 29/01/2014**

**[RCT filter used to exclude RCT's]**

## **MEDLINE OVID format, sensitivity- maximising version (2008)**

#1 randomized controlled trial.pt.

#2 controlled clinical trial.pt.

#3 randomized.ab.

#4 placebo.ab.

#5 drug therapy.fs.

#6 randomly.ab.

#7 trial.ab.

#8 group.ab.

#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8

#10 exp animals/ not humans.sh.

#11 9 not 10

#12 silver.mp. or silver compounds/ or silver nitrate/ or silver sulfadiazine/

#13 infection.mp. or wound infection/

#14 chronic.mp. or chronic disease/

#15 wound.mp. or wound healing/ or skin ulcer/

#16 (#12 and #13 and #14 and #15) not 11

## **Medline search strategy, OVID format, sensitivity- and precision-maximizing version (2008)**

#1 randomized controlled trial.pt.

#2 controlled clinical trial.pt.

#3 randomized.ab.

#4 placebo.ab.

#5 clinical trials as topic.sh.



#6 randomly.ab.

#7 trial.ti.

#8 #1 or #2 or #3 or #4 or #5 or #6 or #7

#9 exp animals/ not humans.sh.

#10 #8 not #9

#11 silver.mp. or silver compounds/ or silver nitrate/ or silver sulfadiazine/

#12 infection.mp. or wound infection/

#13 chronic.mp. or chronic disease/

#14 wound.mp. or wound healing/ or skin ulcer/

#15 (#11 and #12 and #13 and #14) not #10

#16 review.ab.

#17 #15 not #16

**EMBASE search strategy, OVID format filter from Wong et al, 2006- used to**

**exclude RCT's**

#1 random:.tw.

#2 placebo:.mp.

#3 double-blind:.tw.

#4 #1 or #2 or #3

#5 silver.mp. or silver chloride/ or silver derivative/ or silver dressing/ or silver impregnation/ or silver nanoparticle/ or silver nitrate/ or sulfadiazine silver/

#6 exp infection/ or infection.mp. or wound infection/

#7 chronic.mp. or chronic wound/

#8 exp wound/ or wound.mp. or wound care/ or wound complication/ or wound healing/

#9 #5 and #6 and #7 and #8

#10 #9 not #4

#11 review.ab.

#12 #10 not #11

**CINAHL**

S1 (MH "Leg Ulcer") OR (MH "Venous Ulcer") OR (MH "Pressure Ulcer") OR (MH "Foot Ulcer") OR "wound"

S2 (MH "Silver") OR (MH "Ionic Silver Dressings") OR (MH "Silver Compounds") OR (MH "Silver Nitrate") OR (MH "Silver Sulfadiazine") OR "silver"

S3 (MH "Infection") or (MH "wound infection") or (MH "chronic wound") OR "infection"

S4 (MH "Case Control Studies") OR (MH "Case Studies") OR (MH "Matched Case Control") OR (MH "One-Shot Case Study") OR (MH "Case Management")

S5 ((MH "Infection") or (MH "wound infection") or (MH "chronic wound") OR "infection")

AND (S1 AND S2 AND S3 AND S4)

# Appendix 4

Data Extraction Form, Outcomes 1&2 (Adapted from Cochrane Wounds group, data extraction form)

Date of Extraction	
Authors	
Bibliographic details of study	
Country of study	
No. of participants at start of study	
Notes/ short description	

## Study eligibility

Study characteristics	Eligibility criteria	Eligibility criteria met?			Location in text or source
		Yes	No	Unclear	
<b>Date of study</b>	2008 onwards	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<b>Type of study</b>	Randomised Controlled Trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<b>Participants</b>	Adults with an infected or heavily colonised chronic wounds	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<b>Type of intervention</b>	Use of silver products	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<b>Type of comparison</b>	Compared to control/ standard treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
<b>Type of outcome measures</b>	-A measure of healing rate/ reduction of infection i.e. time to complete wound healing, changes in wound area, resolution of infection/exudate/ inflammation -Adverse effects	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
INCLUDE <input type="checkbox"/>		<input type="checkbox"/> EXCLUDE			
Reason for exclusion					

**Do not proceed if study is excluded from the review**

Trial Characteristics

	<b>Description as stated in report/ paper</b>
<b>Aim of study</b> (e.g. efficacy, equivalence etc.)	
<b>Study Design</b>	
<b>Method of Randomisation</b>	
<b>Start date</b>	
<b>End date</b>	
<b>Duration of participation</b> (from recruitment to follow-up)	
<b>Ethical approval needed/ obtained for the study</b>	Yes <input type="checkbox"/> No <input type="checkbox"/> Unclear <input type="checkbox"/>

Participants/ population

	<b>Description</b> (include comparative information for each intervention or comparison group if available)
<b>Population description</b> (from which study participants are drawn)	
<b>Setting</b> (including location and social context)	
<b>Inclusion/ Exclusion criteria</b>	
<b>Method of recruitment of participants</b> (phone, mail, clinic patients)	
<b>Informed consent obtained</b>	Yes <input type="checkbox"/> No <input type="checkbox"/> Unclear <input type="checkbox"/>

<b>Baseline imbalances</b>	
<b>Withdrawals and exclusions, with reasons</b>	
<b>Patient Characteristics;</b> <b>i.e.</b> Age Sex Race/ Ethnicity Severity of illness Co-morbidities Socio-demographic factors	
<b>Wound Characteristics;</b> <b>i.e.</b> Type of wound Recurrent wound? Duration of wound Wound area	

Study Intervention details

	<b>Description as stated in report/ paper</b>
<b>Groups involved in intervention</b>	
<b>No. randomised to groups</b>	
<b>Theoretical basis</b> (include key references)	
<b>Silver product used</b>	
<b>Controls/ comparison treatment</b>	
<b>Treatment protocol</b>	
<b>Care setting</b>	
<b>Care providers</b>	

<b>Co-interventions</b>	
<b>Duration of intervention</b>	
<b>Economic information</b>	

Analysis

	<b>Description as stated in report/ paper</b>
<b>What population analysis was performed at baseline?</b>	
<b>What wound analysis was performed at baseline?</b>	
<b>What infection analysis was performed?</b>	

OUTCOME 1- Outcomes in study extracted related to the effectiveness of silver

	<b>Description as stated in report/ paper</b>
<b>Definition of outcome(s)</b>	
<b>Timing of assessment (s)</b>	
<b>Person measuring/ reporting outcome</b>	
<b>Assumed risk estimate</b> (e.g. baseline population risk noted in background)	
<b>Length of follow-up</b>	
<b>Statistics used to assess outcome</b>	
<b>Results of outcome(s)</b>	

OUTCOME 2- Adverse Effects- (information to be extracted as suggested by The Centre of Reviews and Dissemination, 2009)

	<b>Description as stated in report/ paper</b>
<b>Report of side-effects of treatment in paper?</b>	
<b>Side-effects of treatment</b>	
<b>Frequency, severity and seriousness of the event(s)</b>	
<b>Method of monitoring of adverse effects (e.g. reported at follow-up/ patient diary)</b>	
<b>Withdrawals from treatment due to adverse effects</b>	

*Quality assessment for outcome 2-* (Questions from Loke, Price and Herxheimer, 2008)

On conduct:

- Are definitions of reported adverse effects given?
- Were the methods used for reporting adverse effects reported?

On reporting:

- Were any patients excluded from the adverse effects analysis?
- Does the report provide numerical data by intervention group?
- Which categories of adverse effects were reported by the investigators?

Author's conclusions

	<b>Description as stated in report/ paper</b>
<b>Limitations of study</b>	
<b>Implication of study</b>	



<b>References to other relevant studies</b>	
---	--

Comments on the Quality of the RCT (use CASP assessment framework)

Extractor's comments on the following:

*-Internal validity*

- *Selection bias*
  
- *Performance bias*
  
- *Measurement bias*
  
- *Attrition bias/ exclusion bias*

*-External validity (Generalizability)-*

# Appendix 5

Table 2- Characteristics of RCTs included in the review

Author and Title	Study objectives	Participants	Intervention (treatment and duration)	Outcome measures
<b>Beele et al (2010)</b>	Observe performance of an ionic silver alginate/ carboxymethyl cellulose dressing on wounds that are critically colonised and report whether the dressing can be used to manage and reduce an "at risk" wound from becoming infected.	36 from the Netherlands and Belgium VLU and PU	Use of an ionic silver alginate/ carboxymethyl cellulose dressing vs control for 4 weeks -no co-interventions stated	-Measures of wound healing -Measures of infection levels
<b>Harding et al (2012)</b>	Compare the wound healing of 2 silver dressings against venous leg ulcers at risk of infection. Primary objective was to show the non-inferiority of Aquacel®Ag to @Urgotul silver.	281 from UK, Germany, France, Denmark and Poland VLU	Use of both silver products for 4 weeks then non-silver product used in each group for 4 weeks. -compression therapy	-Measures of wound healing -Measures of infection levels
<b>Lazareth et al (2012)</b>	Assess the ability of a silver lipidocolloid contact layer to promote the healing process of VLU presenting inflammatory signs suggesting heavy bacterial colonisation and delayed healing, in comparison with the same wound dressing not impregnated with silver salts.	102 from France VLU	Use of silver product vs control for 4 weeks. Then both groups were treated with the same treatment as the control. -compression therapy & secondary dressing of Tetra medical applied	-Measures of wound healing -Measures of infection levels
<b>Miller et al (2010)</b>	Compare the clinical effectiveness of cadexomer iodine and nanocrystalline silver. The nul hypothesis was posed, that there is no expected differences in healing rates.	281 from Australia LU	Use of iodine vs nanocrystalline silver products for 12 weeks -compression therapy	-Measures of wound healing
<b>Woo et al (2012)</b>	Aims to evaluate if topical silver dressings that consist of alginate powder is effective in managing chronic wounds that exhibit signs of critical colonisation and promote wound healing	34 from Canada A range of chronic leg ulcers and foot ulcers.	Use of silver alginate powder dressing vs control for 4 weeks -Appropriate plantar pressure redistribution devices were used for some patients.	-Measures of wound healing -Measures of infection levels

VLU- Venous leg ulcer

PU- Pressure ulcer

LU- Leg ulcer

# Appendix 6

## Characteristics of observational studies included in the review

Study authors and Date	Trial characteristics	Study Aims/objectives	Participants	Intervention	Study conclusions/ outcomes
<b>Bhattacharyya and Bradley (2006)</b>	Single case study	The report presents the difficulties encountered when managing a wound colonised with MRSA, which was successfully treated with nanocrystalline silver.	1 patient, London hospital Lewisham	Treatment of a patient's chronic knee wound with nanocrystalline silver releasing dressing.	They speculate that the use of nanocrystalline silver may have reduced bacterial loading at the wound site and thereby decreased the stimulus for autoimmune reaction in patients with psoriasis.
<b>Coutts and Sibbald (2005)</b>	Single centre, open-label case series	Evaluate the clinical improvement in chronic wounds over a 4 week period, whilst undergoing treatment with silver containing hydrofiber dressing.	30 participants, Canada Wounds included: -4 diabetic neuropathic foot ulcers -13 venous stasis ulcers -4 pressure ulcers -9 miscellaneous wounds	4 week application of silver containing hydrofiber dressing to chronic wounds.	Majority of wounds decreased in size (70%) with decrease exudate, decreased purulence and resolution of surface slough (75%). There was also an increased quantity of granulation tissue. A de-sloughing action was also seen in pts. with pre-existing slough at baseline (54% had peri-wound maceration at baseline, 85% of these resolved).
<b>Richards and Chadwick (2011)</b>	A single centre, open, non-randomised case series.	Evaluate the effectiveness of Mepilex Ag in the management of signs and symptoms of wound infection in a number of diabetic foot ulcers (DFU).	15 participants. Inpatients and outpatients of a specialist podiatry clinic who presented with active DFU's with local signs of infection	Each participant was treated according to local clinical practice and evaluated over a 4 week period during the wound management with Mepilex Ag.	-Erythema, oedema and heat (infection related symptoms) were reduced by the end of the study when compared with the baseline -Exudate levels were also reduced at end of study when compared to baseline. With 93.3% (14/15) of DFU producing mild or no exudate. -Pain scores reduced over the course of the study. -Trend of a decline in wound size was noted over the course of the study -100% of investigators rated the treatment as "good" or "very good". -only 1 AE
<b>Truchetet et al (2012)</b>	Prospective observational study	To describe the motivations for using a silicone, silver-releasing dressing and the type of wounds treated with this dressing, and to evaluate the short-term impact on wound characteristics.	794 participants Adult patients in the community. A range of wound types, chronic & acute - evaluated independently at baseline.	Use of a silicone, silver releasing dressing (Mepilex Ag) on wounds.	The primary rationale for prescription of a silver dressing was treatment of possible wound infection.

## Appendix 7

Study authors and date	No. of participants	Trial duration (weeks)	Type of silver product	Wound type	Results related to this outcome
Beele et al (2010)	36	4	Silver alginate/ carboxymethyl-cellulose dressing	PU, VLU	-Greater improvement in wound healing in test treatment -Greater reduction in levels of wound infection in test treatment.
Lazareth et al (2008)	102	8	Urgotul ®silver (silver lipidocolloid)	VLU	-Greater improvement in wound healing in test treatment -Greater reduction in levels of wound infection in test treatment at week 4.
Meaume et al (2005)	99	4	Silver releasing hydro-alginate	VLU, PU	-mASEPSIS score did not differ significantly between groups in first 2 wks of treatment -4 wk closure rate was statistically significant in silver test group (p=0.024)
Munter et al (2006)	619	4	Silver-releasing foam	Ulcers of varying aetologies	-Statistically significant (p<0.05) difference in wound area reduction in favour of silver test group. -Decreased odour, reduced exudates, improved pain
Verdú et al (2004)	125	6	Charcoal silver dressing	PU with wound infection	-Test group had a statistically significant (p=0.003) positive effect on bacterial management when compared to control. -Study authors state healing time was reduced for test group.
Woo et al (2010)	34	4	Silver alginate powder (arglaes powder)	A range of chronic leg and foot ulcers	-Greater rate of wound healing in silver test treatment group -Greater reduction of infection levels in the silver test treatment group
<b>Randomised studies without clear controls</b>					
Harding et al (2012)	281	8	Aquacel ®Ag vs Urgotul ®silver	VLU	-Both dressings were effective at promoting healing and reducing infection levels.
Miller et al (2010)	281	12	Nanocrystalline (Acticoat, acticoat absorbant, acticoat 7)	Leg ulcer	-Greater healing rate in first two weeks of treatment than the iodine treatment. -More effective in wounds that were older, larger and had more exudate

## Appendix 8

Study authors and date	Country of Study	Patient characteristics	Wound characteristics	Care setting
Beele et al (2010)	Netherlands and Belgium	<ul style="list-style-type: none"> <li>-pop predominantly women</li> <li>-mean age 73.4 silver, 73.5 control group</li> <li>-BMI; 30.5 and 27.1 in silver and control</li> <li>-Diabetes; 33.3% silver, 22.2% control</li> <li>-Hypertension; 33.3% silver, 27.5% control</li> </ul>	<ul style="list-style-type: none"> <li>PU &amp; VLU</li> <li>-History of leg ulcer; 50% silver, 33.3% control</li> <li>-History of PU; 11.1% silver, 22.2% control</li> </ul>	Not stated, however does state the patient was "visited weekly" therefore may be in community setting.
Lazareth et al (2008)	France	<ul style="list-style-type: none"> <li>-pop predominantly women</li> <li>-mean age; 74</li> <li>-mean BMI; 28.9kg/m<sup>2</sup></li> <li>-18.6% were diabetics</li> <li>-32.4% had history of venous thrombosis</li> </ul>	<ul style="list-style-type: none"> <li>VLU</li> <li>-79.4% were viewed as stagnated by the investigators</li> <li>-leg ulcers were present for 11 months on average and were recurrent</li> </ul>	-71% of patients were outpatients, recruited from hospital dermatology and vascular medicine.
Woo et al (2010)	Canada	<ul style="list-style-type: none"> <li>-Study sample predominantly male</li> <li>-Mean age; 55.29 silver, and 56.9 in control group</li> </ul>	<ul style="list-style-type: none"> <li>A range of chronic wounds present for over a month.</li> <li>-most ulcers located below the ankle</li> </ul>	Wound care clinic
Harding et al (2012)	UK, Germany, France, Denmark and Poland	<ul style="list-style-type: none"> <li>-pop predominantly women in both treatment groups</li> <li>-Mean age; 68.72 in Aquacel®Ag group and 71.21 in Urgotul®silver group.</li> </ul>	<ul style="list-style-type: none"> <li>VLU, ABPI= 0.8 or greater, duration less than 12 months, 5-40cm<sup>2</sup></li> <li>-majority of ulcers were classified as deteriorating or had shown no progress in wound healing</li> </ul>	Participants home or in clinic
Miller et al (2010)	Australia	<ul style="list-style-type: none"> <li>-58.6% of participants were female</li> <li>-Mean age; 79.67</li> </ul>	<ul style="list-style-type: none"> <li>Leg ulcers, ABPI= 0.6 or above</li> <li>-Majority of wounds were diagnosed as being venous in origin</li> <li>-Most wounds were located on the lower leg</li> </ul>	Community district nursing patients, care provided in patients' homes or in clinic